ArticleNature medicine2025
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates.
Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Bundibugyo Virus Disease: Diagnostics and Medical Countermeasures for a Neglected Ebolavirus.Viruses · 2026Review
- Pharmacokinetics, Safety, and Tolerability of Obeldesivir in Healthy Japanese and White Participants.European journal of drug metabolism and pharmacokinetics · 2026Article
- Bundibugyo virus-perspectives for the current outbreak.Npj viruses · 2026Article
- Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review.Pharmaceutics · 2026Review
- Article
- Post-exposure prevention in Marburg virus outbreaks: potential role of remdesivir in emergency response.Annals of medicine and surgery (2012) · 2025Article
- Increasing Occurrence of Marburg Virus Outbreaks in Africa: Risk Assessment for Public Health.Microbial biotechnology · 2025Review
- Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeys.Nature communications · 2025Article
- Article
- Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus.Nature communications · 2025Article
- The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection.Science advances · 2025Article
- Stopping Marburg virus in its tracks.Nature reviews. Microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
The recent outbreak of Marburg virus (MARV) in Rwanda underscores the need for effective countermeasures against this highly fatal pathogen, with case fatality rates reaching 90%. Currently, no vaccines or approved treatments exist for MARV infection, distinguishing it from related viruses such as Ebola. Our study demonstrates that the oral drug obeldesivir (ODV), a nucleoside analog prodrug, shows promising antiviral activity against filoviruses in vitro and offers significant protection in animal models. Here with cynomolgus macaques (n = 6), a 10 day regimen of once-daily ODV, initiated 24 h after exposure, provided 80% protection against a thousandfold lethal MARV challenge, delaying viral replication and disease onset. Transcriptome analysis revealed that early adaptive responses correlated with successful outcomes. Compared with intravenous options, oral antivirals such as ODV offer logistical advantages in outbreak settings, enabling easier administration and broader contact coverage. Our findings support the potential of ODV as a broad-spectrum, oral postexposure prophylaxis for filoviruses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.